Immunotherapy is emerging as a vital approach in cancer treatment, with advancements showing a modest increase in survival rates. The conversation highlights the potential of engineering T cells to enhance their effectiveness against tumors, balancing the need for experience and youthfulness in these immune soldiers. The challenge lies in expanding T cells that can recognize cancer while maintaining their ability to act decisively.
